Pralidoxime: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
|||
| (10 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Also known as 2-PAM | ||
*Type: [[Antidote]] | |||
*Dosage Forms: | *Dosage Forms: | ||
*Common Trade Names: | *Common Trade Names: Protopam | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 8: | Line 9: | ||
*1-2gm IV over 5-10min | *1-2gm IV over 5-10min | ||
*Continuous infusion of 500mg/hr if no initial response | *Continuous infusion of 500mg/hr if no initial response | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 16: | Line 16: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Unknown | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult - no requirements from manufacturer, but given that it is excreted in the urine dosage reduction is recommended. | ||
**Pediatric | **Pediatric | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult - no adjustments recommended by manufacturer. | ||
**Pediatric | **Pediatric | ||
| Line 30: | Line 30: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[Laryngospasm]] | |||
*Myasthenic crisis in patients with Myasthenia gravis | |||
*Hepatitis | |||
===Common=== | ===Common=== | ||
*Blurry vision | |||
*Diplopia | |||
*Nausea | |||
*Tachycardia | |||
*Hypertension | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: Apparent: 74 to 77 minutes, IM/IV exposure: 3 to 4 hours | ||
*Metabolism: | *Metabolism: Hepatic | ||
*Excretion: | *Excretion: Urine | ||
*Mechanism of Action: Displaces an organophosphate from acetylcholinesterase (if given early) | *Mechanism of Action: Displaces an organophosphate from acetylcholinesterase (if given early before irreversible enzyme binding occurs, aka "aging") | ||
==Comments== | ==Comments== | ||
==See Also== | ==See Also== | ||
[[Organophosphate Toxicity]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Toxicology]] | |||
Latest revision as of 22:53, 13 March 2021
General
- Also known as 2-PAM
- Type: Antidote
- Dosage Forms:
- Common Trade Names: Protopam
Adult Dosing
Organophosphate toxicity
- 1-2gm IV over 5-10min
- Continuous infusion of 500mg/hr if no initial response
Pediatric Dosing
Organophosphate toxicity
- 20-40mg/kg (up to 1gm) IV over 5-10min
- 5-10mg/kg/hr if no initial response
Special Populations
- Pregnancy Rating: C
- Lactation risk: Unknown
- Renal Dosing
- Adult - no requirements from manufacturer, but given that it is excreted in the urine dosage reduction is recommended.
- Pediatric
- Hepatic Dosing
- Adult - no adjustments recommended by manufacturer.
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Laryngospasm
- Myasthenic crisis in patients with Myasthenia gravis
- Hepatitis
Common
- Blurry vision
- Diplopia
- Nausea
- Tachycardia
- Hypertension
Pharmacology
- Half-life: Apparent: 74 to 77 minutes, IM/IV exposure: 3 to 4 hours
- Metabolism: Hepatic
- Excretion: Urine
- Mechanism of Action: Displaces an organophosphate from acetylcholinesterase (if given early before irreversible enzyme binding occurs, aka "aging")